Assessment of PRMT6-dependent alternative splicing in pluripotent and differentiating NT2/D1 cells
Protein arginine methyltransferase 6 (PRMT6) is a well-characterized epigenetic regulator that methylates histone H3 at arginine 2 (H3R2me2a) in both promoter and enhancer regions, thereby modulating transcriptional initiation. We report here that PRMT6 also regulates gene expression at the post-transcriptional level in the neural pluripotent state and during neuronal differentiation of NT2/D1 cells. PRMT6 knockout causes widespread alternative splicing changes in NT2/D1 cells, most frequently cassette exon alterations. Most of the PRMT6-dependent splicing targets are not transcriptionally affected by the enzyme and regulated in an H3R2me2a-independent manner. However, for a small subset of splicing events, the PRMT6-mediated deposition of H3R2me2a overlaps with the splice site, suggesting a potential dual function in both transcriptional and co-/post-transcriptional regulation. The splicing targets of PRMT6 include ribosomal proteins, splicing factors, and chromatin-modifying enzymes such as PRMT4, DNMT3B, and ASH2L, some of which are associated with differentiation decisions. Taken together, our results in NT2/D1 cells show that PRMT6 exerts predominantly H3R2me2a-independent functions in RNA splicing, which may contribute to pluripotency and neuronal identity.
Authors
- Uta‐Maria Bauer (ORCID: https://orcid.org/0000-0003-1344-9117)
- Kathi Zarnack (ORCID: https://orcid.org/0000-0003-3527-3378)
- Oliver Roßbach (ORCID: https://orcid.org/0000-0002-1172-0359)
- Caroline Bouchard
- Jonas Busam
- Matthias Eudenbach
Institutions
- Goethe University Frankfurt (DE)
- Justus-Liebig-Universität Gießen (DE)
- University of Würzburg (DE)
- Institute of Molecular Biology (DE)
Publication Details
- Journal
- Life Science Alliance
- Published
- 2025-02-03
- DOI
- https://doi.org/10.26508/lsa.202402946
- Primary Topic
- Cancer-related gene regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft
- José Carreras Leukämie-Stiftung